Press Releases OncoCyte Corporation

Equities

Delayed Nasdaq Other stock markets 01:58:16 2024-05-07 pm EDT			5-day change	1st Jan Change
2.8 ^USD	+1.08%		+12.45%	+12.00%

Apr. 25	OncoCyte Corporation announced that it has received $15.807655 million in funding	CI
Apr. 16	Broadwood Capital, Inc. Engages with OncoCyte Corporation	CI

PRISM MarketView Spotlights Oncocyte Corporation as it Works to Disrupt the Precision Diagnostics Marketplace	09:19am	AQ
ONCOCYTE REPORTS FULL YEAR 2023 FINANCIAL RESULTS	Apr. 15	AQ
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules	Apr. 15	AQ
Oncocyte Reports Full Year 2023 Financial Results	Apr. 12	AQ
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules	Apr. 11	AQ
Oncocyte : and Bio-Rad Partner on Global Launch of Transplant Assay - Form 8-K	Apr. 11	PU
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay	Apr. 11	AQ
Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results	Apr. 09	AQ
Oncocyte to Present at the Sequire Investor Summit in Puerto Rico	Jan. 16	AQ
Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays	Dec. 06	AQ
OncoCyte: Q3 Earnings Snapshot	Nov. 09	AQ
Oncocyte Reports Third Quarter 2023 Financial Results	Nov. 09	AQ
Oncocyte to Announce Third Quarter 2023 Financial Results	Nov. 03	AQ
OncoCyte : Change in Certifying Accountants - Form 8-K	23-10-05	PU
Oncocyte : Investor Presentation	23-10-03	PU
ONCOCYTE'S VITAGRAFTTM KIDNEY IDENTIFIES TRANSPLANT REJECTION 10 MONTHS EARLIER	23-09-19	AQ
Oncocyte : Investor Presentation	23-08-21	PU
OncoCyte: Q2 Earnings Snapshot	23-08-10	AQ
VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients	23-07-25	AQ
Oncocyte Announces 1-For-20 Reverse Stock Split	23-07-24	AQ

No results for this search